March 15th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.
Phase 3 Trial of Pembrolizumab Meets Primary PFS End Point in Endometrial CancerFebruary 3rd 2023
The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.
Follow-Up of Lenvatinib/Pembrolizumab Elicits Efficacy in Endometrial CancerJanuary 30th 2023
According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.
Dostarlimab Achieves Significant PFS Improvement in Primary Advanced or Recurrent Endometrial CancerDecember 2nd 2022
The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.
Dostarlimab Therapy in Recurrent Metastatic Endometrial Cancer: The GARNET TrialSeptember 26th 2022
Centering discussion on safety and efficacy data from the GARNET trial, Bhavana Pothuri, MD, reflects on the role of dostarlimab therapy in patients with recurrent metastatic endometrial cancer.
Case Overview: A 64-Year-Old Woman With dMMR Metastatic Endometrial CancerSeptember 26th 2022
Expert oncologist Bhavana Pothuri, MD, reviews the diagnosis and treatment of a 64-year-old woman who presents and recurs with mismatch repair-deficient (dMMR) endometrial cancer (EC).
Pembrolizumab Continues to Show Robust Antitumor Activity in MSI-H/dMMR Endometrial CancerSeptember 16th 2022
Robust and durable antitumor activity continues to be shown with pembrolizumab in patients with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.
Lenvatinib/Pembrolizumab Benefit Maintained in Advanced Endometrial CancerSeptember 11th 2022
After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.
Lenvatinib Plus Pembrolizumab Improves Time to Deterioration in QOL Over Chemo in Endometrial CancerAugust 22nd 2022
According to patient-reported outcomes for those with endometrial cancer, the combination of lenvatinib plus pembrolizumab was favored over treatment of physician's choice.
FDA Approves New Pembrolizumab CDx to Identify pMMR in Endometrial CancerAugust 12th 2022
The FDA has approved a label expansion for the VENTANA MMR RxDx panel to identify patients with dMMR solid tumors and pMMR endometrial cancer who are eligible for treatment with pembrolizumab.
Adding Vistusertib to Anastrozole Improves Safety and PFS in Patients with Endometrial CancerJune 21st 2022
Improvement in progression-free survival and safety demonstrated with the addition of vistusertib to anastrozole vs anastrozole alone in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial CancerJune 8th 2022
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Lenvatinib/Pembrolizumab Combo Improves Efficacy of Next Line of Therapy in Advanced Endometrial CancerJune 5th 2022
An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.
FDA Approves Pembrolizumab for Select Patients With MSI-H/dMMR Advanced Endometrial CarcinomaMarch 21st 2022
Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.